Blog

Rahul Gosain: FDA approval of Fruquintinib from FRESCO2 and how it fits in our Rx paradigm with N. Arvind Dasari

Photos of Rahul and Rohit Gosain, and Arvind Dasari

Apr 29, 2024, 07:58

Rahul Gosain: FDA approval of Fruquintinib from FRESCO2 and how it fits in our Rx paradigm with N. Arvind Dasari

Rahul Gosain, Co-Founder of Oncology Brothers podcast and Director of Regional Infusion Services and Medical Director at Wilmot Cancer Institute, recently shared on LinkedIn:

“GISeries: In this episode, we get a chance to discuss FDA approval of Fruquintinib from FRESCO2 and how it fits in our treatment paradigm with N. Arvind Dasari.

Full Interview:
– On Targeted Oncology,
– On OncBrothers,
– Also on the ‘Oncology Brothers’ podcast.”

View the attached video.
Source: Rahul Gosain/LinkedIn

cancer colorectal cancer CRC FDA FDA approval FRESCO2 trial Fruquintinib N. Arvind Dasari OncoDaily Oncology Oncology Brothers Rahul Gosain refractory CRC Targeted Oncology Wilmot Cancer Institute

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites

Special Coverage